Mereo Biopharma Group PLC 8-K filings

Mereo BioPharma announced Q2 2026 results, highlighting a significant option and license agreement for alvelestat with Sentynl Therapeutics and an extended cash runway into late 2027.

Mereo BioPharma Group plc has entered into an option and license agreement with Sentynl Therapeutics, Inc. for the U.S. commercial and global manufacturing rights to alvelestat for alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

Mereo BioPharma Group plc announced that all resolutions proposed at its 2026 Annual General Meeting of Shareholders were passed, including the adoption of annual accounts and the re-appointment of auditors and directors.

Mereo BioPharma reports Q1 2026 financial results, highlighting progress in setrusumab's regulatory engagement for pediatric OI and ongoing partnership discussions for alvelestat.

Mereo BioPharma announced Q1 2026 financial results, highlighting progress in regulatory discussions for setrusumab in pediatric OI and active partnership talks for alvelestat.

Dr. Annalisa Jenkins will not seek re-election to Mereo BioPharma Group PLC's Board of Directors at the upcoming 2026 annual general meeting.

Mereo BioPharma announced its full year 2025 financial results, highlighting setrusumab's failure to meet primary endpoints in Phase 3 OI studies despite positive secondary outcomes, and an extended cash runway into mid-2027.

Mereo BioPharma announced an updated cash runway to mid-2027 and reported that its setrusumab Phase 3 studies in osteogenesis imperfecta did not meet primary endpoints for fracture reduction.

Mereo BioPharma announced that its Phase 3 ORBIT and COSMIC studies for setrusumab in osteogenesis imperfecta did not meet primary endpoints for fracture rate reduction, despite showing significant improvements in bone mineral density.

Mereo BioPharma reports Q3 2025 financial results, highlighting setrusumab Phase 3 data expected by year-end and cash runway into 2027.

Mereo BioPharma reported its second quarter 2025 financial results, highlighting progress in its setrusumab and alvelestat programs and maintaining its cash runway guidance into 2027.

Mereo BioPharma Group PLC and Ultragenyx Pharmaceutical Inc. announced that the Phase 3 Orbit study for UX143 (setrusumab) in osteogenesis imperfecta is progressing as planned towards final analysis by year-end, with an acceptable safety profile.

Mereo BioPharma Group PLC held its 2025 Annual General Meeting of Shareholders on May 13, 2025, where all resolutions were passed as proposed, except for the frequency of advisory votes on executive compensation.

Mereo BioPharma announced its Q1 2025 financial results, highlighting progress in the Phase 3 Orbit study for setrusumab and a cash runway into 2027.

Mereo BioPharma announced its full year 2024 financial results, highlighting progress in its lead programs and a cash position expected to fund operations into 2027.

Mereo BioPharma provides an update on its lead clinical programs, including the Phase 3 Orbit study of setrusumab and the positive EMA opinion on European Orphan Designation Application for alvelestat.

Mereo BioPharma amended its licensing agreement with AstraZeneca, potentially increasing payments up to $114.3 million, and reported a net loss of $15 million for Q3 2024, while highlighting positive clinical progress for its lead drug candidates.

Mereo BioPharma announced positive Phase 2 results for setrusumab in osteogenesis imperfecta (OI) and secured funding to extend operations into 2027.

Mereo BioPharma has announced a $50 million underwritten offering of American Depositary Shares (ADSs) priced at $3.99 per ADS.

Interim data from the Phase 2 portion of the Phase 2/3 Orbit study shows setrusumab significantly reduced fracture rates and improved bone mineral density in patients with osteogenesis imperfecta.

Mereo BioPharma Group PLC held its 2024 Annual General Meeting on May 23, 2024, where all proposed resolutions were passed, including the re-election of three directors.

Mereo BioPharma announced its Q1 2024 financial results, highlighting progress in clinical trials and pre-launch activities, with cash runway extended into 2026.

Mereo BioPharma has extended its cooperation agreement with Rubric Capital, allowing director Justin Roberts to remain on the board until after the 2025 annual shareholder meeting.

Mereo BioPharma announced its 2023 financial results, highlighting progress in its rare disease programs and a strong cash position to fund operations into 2026.